EICHORPublic-registry site landscape for NCT07700758, “A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01)”, a Malignant Neoplasm study sponsored by Merck Sharp & Dohme LLC. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07700758 (registry record) |
| Study title | A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01) |
| Official title | LIGHTBEAM-U01 Substudy 01E: A Phase 2 Substudy to Evaluate the Safety and Efficacy of Belzutifan in Participants With Solid Tumors |
| Sponsor | Merck Sharp & Dohme LLC |
| Condition(s) | Malignant Neoplasm |
| Phase | PHASE2 |
| Listed sites | 0 |
Patient-friendly overview of this study: eichor.com/study/NCT07700758.
Eichor generates a preliminary site-risk snapshot for NCT07700758 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
More from Merck Sharp & Dohme LLC
← Eichor home · All tracked trials · Malignant Neoplasm studies · Weekly briefs
